StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson iNVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q3 2026
998
Period ended Sep 30, 2026
Change on a year earlier
+7.4%
929 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedINVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026998+7.4%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 20261,015+2.3%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 20261,038+15.0%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 2025986-7.2%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 2025929-11.4%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 2025992-5.9%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 2025903-14.5%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 20241,063+5.1%Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 20241,049+1.9%Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 20241,054+2.2%Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 20241,056+1.1%Form 10-Q (filed 2025-04-23) ↗
Q4 2023Dec 31, 20231,011+0.3%Form 10-K (filed 2026-02-11) ↗
Q3 2023Oct 1, 20231,029-0.2%Form 10-Q (filed 2024-10-23) ↗
Q2 2023Jul 2, 20231,031-2.2%Form 10-Q (filed 2024-07-25) ↗
Q1 2023Apr 2, 20231,044-0.4%Form 10-Q (filed 2024-05-01) ↗
Q4 2022Jan 1, 20231,008-1.9%Form 10-K (filed 2025-02-13) ↗

Breakdown

What makes up invega sustenna / xeplion / invega trinza / trevicta (paliperidone palmitate) — worldwide sales ($m)

Cite this data

StockData. (2026). Johnson & Johnson INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M) ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_invega

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.